AU6284194A - Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) - Google Patents

Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)

Info

Publication number
AU6284194A
AU6284194A AU62841/94A AU6284194A AU6284194A AU 6284194 A AU6284194 A AU 6284194A AU 62841/94 A AU62841/94 A AU 62841/94A AU 6284194 A AU6284194 A AU 6284194A AU 6284194 A AU6284194 A AU 6284194A
Authority
AU
Australia
Prior art keywords
fgf
treatment
growth factor
fibroblast growth
motor neuron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62841/94A
Inventor
Richard A. Hughes
Dan Lindholm
Michael Sendtner
Hans F. E. Thoenen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU6284194A publication Critical patent/AU6284194A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62841/94A 1993-03-12 1994-03-11 Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) Abandoned AU6284194A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3061193A 1993-03-12 1993-03-12
US030611 1993-03-12
PCT/EP1994/000764 WO1994020125A1 (en) 1993-03-12 1994-03-11 Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)

Publications (1)

Publication Number Publication Date
AU6284194A true AU6284194A (en) 1994-09-26

Family

ID=21855051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62841/94A Abandoned AU6284194A (en) 1993-03-12 1994-03-11 Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)

Country Status (4)

Country Link
AU (1) AU6284194A (en)
IL (1) IL108950A0 (en)
WO (1) WO1994020125A1 (en)
ZA (1) ZA941729B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111786A0 (en) * 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
ATE226444T1 (en) * 1998-03-12 2002-11-15 Genentech Inc USE OF FGF-5 POLYPETIDES TO PREVENT RETINAL NEURON DEATH AND TREAT OCCULAR DISEASES
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
AU5866600A (en) * 1999-06-29 2001-01-31 Eli Lilly And Company The use of human fgh-8 polypeptides as neurotrophic agents
CA2384696A1 (en) * 1999-10-02 2001-04-12 The Government Of The United States Of America Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen
ES2363765T3 (en) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR AGONISTS.
EP1788094A4 (en) * 2004-08-24 2009-05-13 Eisai R&D Man Co Ltd Method of distinguishing spinal cord neuron type targeting corl1 gene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells

Also Published As

Publication number Publication date
WO1994020125A1 (en) 1994-09-15
ZA941729B (en) 1994-10-13
IL108950A0 (en) 1994-06-24

Similar Documents

Publication Publication Date Title
AU697619B2 (en) Enzymatic treatment of cocoa
AU7250294A (en) Treatment of multidrug resistant diseases
AU4997093A (en) Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes
AU1173195A (en) Treatment of immunoregulatory disorders
AU4350296A (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
EP0690673A4 (en) Systemic gene treatment of connective tissue diseases
AU5960394A (en) Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
AU6284194A (en) Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)
AU1059095A (en) Treatment of viral disease with cd40l peptide
AU5758594A (en) Treatment of viral infections
AU3965497A (en) Methods of treatment of eye trauma and disorders
AU2653095A (en) Fibroblast growth factor-14
AU8113294A (en) Treatment of a patient prior to transplantation
AU2653195A (en) Fibroblast growth factor 11
AU5518694A (en) Treatment of a group of related disorders
AU5340594A (en) Skin treatment
AU7877894A (en) Treatment of hiv infection with humic acid
AU2697995A (en) Fibroblast growth factor 13
AU5014893A (en) Tissue heart valve with concentric mating stents
AU6829696A (en) Treatment of solutions
AU1041297A (en) Fibroblast growth factor fgf-10
AU7103594A (en) Treatment of neonatal hyperbilirubin with metalloporphyrin
AU1068495A (en) Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
AU7112194A (en) Inhibition of basic fibroblast growth factor with oligonculeotides
AU7572696A (en) Treatment of diabetes with a glucokinase gene